Erenumab under review in US and EU
R&D chief Michael Hayden to leave at year end.
BioSensics’ HDWear provides real-time motor function scores in Huntington’s patients.
Unlike AZ’s Soriot, Schultz “couldn’t refuse” top job at Teva.
Allergan generics buyout left Teva with $35m debts
Report raises concerns about outcome of MYSTIC trial.
SD-809 will be vital for Teva if approved.
Evaluate predicts sales could approach $8bn if approved.
Payment ends decade of litigation.